In a 42-year-old male with newly diagnosed type 2 diabetes mellitus, hypertension, alcoholic liver disease, and coronary artery disease (with left ventricular hypertrophy, diastolic dysfunction, and preserved ejection fraction), who is currently taking metformin, empagliflozin, telmisartan, amlodipine, hydrochlorothiazide, aspirin, rosuvastatin, and uric‑acid‑lowering therapy, should any additional medication be added or should the current regimen be continued?

Add a Beta-Blocker Immediately

Your patient requires the addition of a beta-blocker to his current regimen. Despite having preserved ejection fraction (EF 56%), he has established coronary artery disease with regional wall motion abnormalities, left ventricular hypertrophy, and diastolic dysfunction—all of which mandate beta-blocker therapy for secondary prevention and to reduce cardiovascular mortality.

Critical Gap in Current Management

Your patient has documented CAD with:

• Regional wall motion abnormality (hypokinesia of mid and apical anterior wall)
• Concentric LVH
• LV diastolic dysfunction
• Multiple cardiovascular risk factors (diabetes, hypertension, obesity)

Yet he is not on a beta-blocker, which is a fundamental omission in post-MI/CAD management. The 2019 ESC Guidelines explicitly recommend beta-blockers in patients with diabetes and CAD to reduce cardiovascular events 1.

Blood Pressure Requires Optimization

His current BP of 150/90 mmHg is above target. The 2020 ISH Guidelines recommend a target BP <130/80 mmHg in patients with diabetes and organ damage 2. He is already on triple antihypertensive therapy (telmisartan 40mg, amlodipine 5mg, hydrochlorothiazide 12.5mg), but not at maximum doses and missing the critical beta-blocker component.

Specific Recommendations for BP Control:

1. Add a beta-blocker (e.g., metoprolol succinate 50mg daily or carvedilol 6.25mg twice daily, titrate upward)
2. Increase telmisartan from 40mg to 80mg daily—the FDA label indicates this is the dose proven for cardiovascular risk reduction 3
3. The ISH guidelines support adding spironolactone if BP remains uncontrolled on 4-drug therapy, but optimize the above first 2

Current Diabetes Management is Appropriate

His diabetes regimen (metformin 1000mg BD + empagliflozin 25mg) is excellent. The 2019 ESC Guidelines specifically recommend empagliflozin in patients with T2DM and CVD to reduce cardiovascular events and death 1. Recent evidence shows empagliflozin improves LV diastolic function and reduces LV mass in patients exactly like yours—T2DM with CAD and diastolic dysfunction 4, 5, 6, 7, 8. His RBS of 94 mg/dL suggests good glycemic control; continue current therapy.

Lipid Management Needs Verification

He's on rosuvastatin/fenofibrate 10/160mg. The 2019 ESC Guidelines recommend an LDL-C target <55 mg/dL (1.4 mmol/L) with ≥50% reduction in patients at very high cardiovascular risk (which he is) 1. Verify his LDL-C level:

• If LDL-C is not at target, increase rosuvastatin dose or add ezetimibe
• If already at maximum statin dose and not at target, consider PCSK9 inhibitor 1

Antiplatelet Therapy Consideration

He's on aspirin 150mg. Given his established CAD with regional wall motion abnormality, verify if he has had a prior MI or PCI:

• If within 12 months of ACS/PCI: He should be on dual antiplatelet therapy (aspirin + P2Y12 inhibitor like ticagrelor or clopidogrel) 1
• If >12 months post-event: Aspirin monotherapy is appropriate, but consider low-dose rivaroxaban 2.5mg BID + aspirin 100mg for very high-risk patients 1

Alcoholic Liver Disease Caveat

His alcoholic liver disease requires caution:

• Assess liver function (AST, ALT, bilirubin, INR, albumin) before intensifying therapy
• Metformin is safe if eGFR >30 mL/min/1.73m² 1
• Beta-blockers are safe in compensated liver disease but use with caution in decompensated cirrhosis
• Statins can be used but monitor liver enzymes
• Counsel on alcohol cessation—this is critical for both liver disease and cardiovascular risk

Weight Management is Essential

BMI = 35.3 kg/m² (Class II obesity). Weight reduction will improve:

• Blood pressure control
• Glycemic control
• LV diastolic function
• Overall cardiovascular risk

Target: 7-10% weight loss through dietary modification and increased physical activity. The empagliflozin will assist with modest weight reduction 1.

Summary of Medication Changes

ADD:

• Beta-blocker (metoprolol succinate 50mg daily or carvedilol 6.25mg BID, titrate up)

INCREASE:

• Telmisartan from 40mg to 80mg daily

VERIFY AND ADJUST:

• LDL-C level → adjust statin/add ezetimibe if needed
• Dual antiplatelet therapy status if recent ACS/PCI
• Liver function tests before intensifying therapy

CONTINUE:

• Metformin 1000mg BD
• Empagliflozin 25mg daily
• Amlodipine 5mg daily
• Hydrochlorothiazide 12.5mg daily
• Aspirin (consider reducing to 100mg daily)
• Rosuvastatin/fenofibrate (adjust based on LDL-C)
• Ursodeoxycholic acid 300mg BD

LIFESTYLE:

• Aggressive alcohol cessation counseling
• Weight loss program targeting 7-10% reduction
• Sodium restriction <2g/day
• Regular aerobic exercise as tolerated

Follow-Up Timeline

• 2 weeks: Check BP response to beta-blocker and increased telmisartan
• 3 months: Reassess BP target achievement, repeat lipid panel, HbA1c, liver function tests, renal function
• 6 months: Repeat echocardiogram to assess LV mass, diastolic function response to optimized therapy